Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
47,000
ISIN
US5324571083
Website
Eli Lilly Metrics
BasicAdvanced
$651B
59.01
$12.29
0.47
$5.40
0.83%
Price and volume
Market cap
$651B
Beta
0.47
52-week high
$972.53
52-week low
$677.09
Average daily volume
4.7M
Dividend rate
$5.40
Financial strength
Current ratio
1.372
Quick ratio
0.569
Long term debt to equity
218.243
Total debt to equity
243.609
Dividend payout ratio (TTM)
43.74%
Interest coverage (TTM)
22.79%
Management effectiveness
Return on assets (TTM)
16.54%
Return on equity (TTM)
77.28%
Valuation
Price to earnings (TTM)
59.01
Price to revenue (TTM)
13.31
Price to book
43.6
Price to tangible book (TTM)
172.59
Price to free cash flow (TTM)
-975.635
Dividend yield (TTM)
0.74%
Forward dividend yield
0.83%
Growth
Revenue change (TTM)
36.38%
Earnings per share change (TTM)
80.99%
3-year revenue growth (CAGR)
18.67%
3-year earnings per share growth (CAGR)
22.24%
3-year dividend per share growth (CAGR)
15.22%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track
WSJ·9 hours ago
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives
Benzinga·2 days ago
Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics
Proactive Investors·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jun10
Eli Lilly
Dividend·Payment
$1.50Per share
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $651B as of May 29, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 59.01 as of May 29, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of May 29, 2025, the dividend rate is $5.4 and the yield is 0.83%. Eli Lilly has a payout ratio of 43.74% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for June 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.